Phosphodiesterase-5 inhibitors: Raynaud's and beyond
Phosphodiesterases (PDE) are a group of ubiquitously present enzymes involved in regulation of various cellular pathways. PDE5 acts to metabolize cyclic guanosine monophosphate (GMP). The various PDE5 inhibitors available are sildenafil, tadalafil, vardenafil, and mirodenafil. We shall discuss the r...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2017-01-01
|
| Series: | Indian Journal of Rheumatology |
| Subjects: | |
| Online Access: | http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2017;volume=12;issue=6;spage=227;epage=231;aulast=Phatak |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841561327196176384 |
|---|---|
| author | Sanat Phatak Sajal Ajmani Vikas Agarwal Durga Prasanna Misra |
| author_facet | Sanat Phatak Sajal Ajmani Vikas Agarwal Durga Prasanna Misra |
| author_sort | Sanat Phatak |
| collection | DOAJ |
| description | Phosphodiesterases (PDE) are a group of ubiquitously present enzymes involved in regulation of various cellular pathways. PDE5 acts to metabolize cyclic guanosine monophosphate (GMP). The various PDE5 inhibitors available are sildenafil, tadalafil, vardenafil, and mirodenafil. We shall discuss the roles of various PDE5 inhibitors in rheumatic diseases. PDE5 inhibitors prevent degradation of cyclic GMP; hence, they have vasodilatory properties which render them useful in the management of secondary Raynaud's phenomenon. They have also demonstrated efficacy in the healing of digital ulcers in systemic sclerosis and potentially prevent the formation of new digital ulcers. Their vasodilatory property has also been utilized in the management of pulmonary arterial hypertension, wherein their ability to favorably affect hemodynamics of a pressure-overloaded right heart is beneficial. Recent evidences have suggested a potential antifibrotic role of these agents, and studies in idiopathic pulmonary fibrosis and systemic sclerosis-associated interstitial lung disease hold promise for future exploration of these agents for these indications. |
| format | Article |
| id | doaj-art-4abd29eb002141bb93a988db46c79dd7 |
| institution | Kabale University |
| issn | 0973-3698 0973-3701 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Indian Journal of Rheumatology |
| spelling | doaj-art-4abd29eb002141bb93a988db46c79dd72025-01-03T01:45:42ZengSAGE PublishingIndian Journal of Rheumatology0973-36980973-37012017-01-01126227231Phosphodiesterase-5 inhibitors: Raynaud's and beyondSanat PhatakSajal AjmaniVikas AgarwalDurga Prasanna MisraPhosphodiesterases (PDE) are a group of ubiquitously present enzymes involved in regulation of various cellular pathways. PDE5 acts to metabolize cyclic guanosine monophosphate (GMP). The various PDE5 inhibitors available are sildenafil, tadalafil, vardenafil, and mirodenafil. We shall discuss the roles of various PDE5 inhibitors in rheumatic diseases. PDE5 inhibitors prevent degradation of cyclic GMP; hence, they have vasodilatory properties which render them useful in the management of secondary Raynaud's phenomenon. They have also demonstrated efficacy in the healing of digital ulcers in systemic sclerosis and potentially prevent the formation of new digital ulcers. Their vasodilatory property has also been utilized in the management of pulmonary arterial hypertension, wherein their ability to favorably affect hemodynamics of a pressure-overloaded right heart is beneficial. Recent evidences have suggested a potential antifibrotic role of these agents, and studies in idiopathic pulmonary fibrosis and systemic sclerosis-associated interstitial lung disease hold promise for future exploration of these agents for these indications.http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2017;volume=12;issue=6;spage=227;epage=231;aulast=PhatakFibrosisphosphodiesterase 5 inhibitorspulmonary hypertensionRaynaud's phenomenonsildenafiltadalafil |
| spellingShingle | Sanat Phatak Sajal Ajmani Vikas Agarwal Durga Prasanna Misra Phosphodiesterase-5 inhibitors: Raynaud's and beyond Indian Journal of Rheumatology Fibrosis phosphodiesterase 5 inhibitors pulmonary hypertension Raynaud's phenomenon sildenafil tadalafil |
| title | Phosphodiesterase-5 inhibitors: Raynaud's and beyond |
| title_full | Phosphodiesterase-5 inhibitors: Raynaud's and beyond |
| title_fullStr | Phosphodiesterase-5 inhibitors: Raynaud's and beyond |
| title_full_unstemmed | Phosphodiesterase-5 inhibitors: Raynaud's and beyond |
| title_short | Phosphodiesterase-5 inhibitors: Raynaud's and beyond |
| title_sort | phosphodiesterase 5 inhibitors raynaud s and beyond |
| topic | Fibrosis phosphodiesterase 5 inhibitors pulmonary hypertension Raynaud's phenomenon sildenafil tadalafil |
| url | http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2017;volume=12;issue=6;spage=227;epage=231;aulast=Phatak |
| work_keys_str_mv | AT sanatphatak phosphodiesterase5inhibitorsraynaudsandbeyond AT sajalajmani phosphodiesterase5inhibitorsraynaudsandbeyond AT vikasagarwal phosphodiesterase5inhibitorsraynaudsandbeyond AT durgaprasannamisra phosphodiesterase5inhibitorsraynaudsandbeyond |